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Abstract
Huntington’s disease (HD) is an inherited, progressive neurological disorder caused by a CAG/polyglutamine repeat
expansion, for which there is no effective disease modifying therapy. In recent years, transcriptional dysregulation has
emerged as a pathogenic process that appears early in disease progression. Administration of histone deacetylase (HDAC)
inhibitors such as suberoylanilide hydroxamic acid (SAHA) have consistently shown therapeutic potential in models of HD,
at least partly through increasing the association of acetylated histones with down-regulated genes and by correcting
mRNA abnormalities. The HDAC enzyme through which SAHA mediates its beneficial effects in the R6/2 mouse model of HD
is not known. Therefore, we have embarked on a series of genetic studies to uncover the HDAC target that is relevant to
therapeutic development for HD. HDAC7 is of interest in this context because SAHA has been shown to decrease HDAC7
expression in cell culture systems in addition to inhibiting enzyme activity. After confirming that expression levels of Hdac7
are decreased in the brains of wild type and R6/2 mice after SAHA administration, we performed a genetic cross to
determine whether genetic reduction of Hdac7 would alleviate phenotypes in the R6/2 mice. We found no improvement in
a number of physiological or behavioral phenotypes. Similarly, the dysregulated expression levels of a number of genes of
interest were not improved suggesting that reduction in Hdac7 does not alleviate the R6/2 HD-related transcriptional
dysregulation. Therefore, we conclude that the beneficial effects of HDAC inhibitors are not predominantly mediated
through the inhibition of HDAC7.
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Introduction
Huntington’s disease (HD) is an autosomal dominant late-onset
progressive neurodegenerative disorder with a mean age of onset of
40 years. Symptoms include psychiatric disturbances, motor
disorders, cognitive decline and weight loss, disease duration is
15–20 years and there are no effective disease modifying treatments
[1]. The HD mutation is an expanded CAG trinucleotide repeat in
the HD gene that is translated into a polyglutamine (polyQ) repeat
in the huntingtin (Htt) protein [2]. Neuropathologically, the disease
is characterized by neuronal cell loss in the striatum, cortex and
other brain regions and the deposition of nuclear and cytoplasmic
polyQaggregates[3,4].The R6/2 mouse model expressesexon 1 of
the human HD gene with more than 150 CAG repeats [5,6]. The
R6/2 phenotype has an early onset and rapid and reproducible
phenotype progression that recapitulates many features of the
human disease. Motor and cognitive abnormalities can be detected
before 6 weeks of age [7,8], and mice are rarely kept beyond 15
weeks. PolyQ aggregates are clearly apparent in some brain regions
from 3 to 4 weeks of age and striatal cell loss has been documented
at later stages [9]. This suggests that the mouse phenotype is
predominantly caused by neuronal dysfunction.
Transcriptional dysregulation occurs early in the molecular
pathology of HD and has been recapitulated across multiple HD
model systems (reviewed in [10]). RNA Affymetrix expression
profiles of brain regions and muscle from both the R6/2
transgenic mouse and knock-in mouse models of HD show high
correlation to expression profiles from HD post-mortem tissue
[11–13]. The molecular mechanisms that underlie these selective
transcriptional disturbances are unknown and remain the subject
of investigation. The control of eukaryotic gene expression in part
depends on the modification of histone proteins associated with
specific genes with the acetylation and deacetylation of histones
playing a critical role in gene expression [14–16]. Studies in
numerous HD models have shown that mutant huntingtin
expression leads to a change in histone acetyltransferase (HAT)
activity and suggest that aberrant HAT activity may contribute to
transcriptional dysregulation in HD [17–19]. Supporting this view,
administration of histone deacetylase (HDAC) inhibitors such as
suberoylanilide hydroxamic acid (SAHA) consistently shows
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5747therapeutic potential in HD models [20–28], at least partly
through increasing the association of acetylated histones with
down-regulated genes and correcting mRNA abnormalities [29].
There are three major classes of mammalian HDACs, based on
their structural homology to the three Saccharomyces cerevisiae
HDACs: rpd3 (class I), hda1 (class II) and sir2 (class III). Class I
comprises HDAC1, -2, -3 and -8, class IIa HDAC4, -5, -7 and -9,
class IIb HDAC6 and -10 and HDAC11 (class IV) shows
homology to both rpd3 and hda1 [30]. Pan-HDAC inhibitors
such as SAHA target the zinc-dependent HDACs 1–11 and not
the NAD+ dependent class III HDACs (the seven sirtuins, SIRT1-
7) [31]. In order to gain insight into which HDACs must be
inhibited in order to alleviate HD-related phenotypes, genetic
approaches have been used to complement pharmacology in
Drosophila melanogaster and Caenorhabditis elegans HD models [19,32].
However, as HDACs show differential levels of evolutionary
conservation [33], the extent to which these studies will inform
drug development in man has yet to be demonstrated.
The molecular mechanisms by which SAHA exerts its beneficial
and toxic effects are currently not clear, nor whether the beneficial
and toxic effects can be dissociated. We therefore need to
systematically interrogate known targets of SAHA genetically in
order to identify the HDAC(s) that present therapeutic targets
relevant to HD. As a consequence, we have embarked on a serried
of genetic crosses between the R6/2 mouse and specific HDAC
knock-out mouse lines. It has previously been shown that in
addition to enzyme inhibition, SAHA treatment selectively
suppresses expression of HDAC7 in vitro [34], thus representing a
potential molecular avenue by which pan-HDAC inhibition exerts
a beneficial effect. We confirmed that chronic administration of
SAHA decreases Hdac7 mRNA expression levels in mouse brain
irrespective of the HD genotype. Hdac7 knockout mice were
previously generated through a targeted inactivation of the
endogenous murine Hdac7 gene [35]. Hdac7 null mice are
embryonic lethal and die at E11.0. However, Hdac7 heterozygote
knockout mice were found to be viable and fertile, with no overt
phenotype. We demonstrate that Hdac7 mRNA and protein levels
are reduced in Hdac7+/2 heterozygous knock-out mice and that
Hdac7 expression is not altered by the presence of the R6/2
transgene. We performed a genetic cross between R6/2 mice and
Hdac7+/2 heterozygotes and found that genetic knock-down of
Hdac7 fails to confer any improvement to a number of
physiological, behavioral and transcriptional phenotypes. We
conclude that neither inhibition of HDAC7 nor its downregulation
contributed significantly to the beneficial effects that we observed
upon administration of SAHA.
Results
The expression of Hdac7 is decreased in R6/2 brain in
response to chronic treatment with SAHA
SAHA has been described as a pan-HDAC enzyme inhibitor
[36,37]. In addition, it was recently shown that treatment of a
number of cell lines with SAHA resulted in the specific down-
regulation of HDAC7 at the mRNA level [34]. To determine
whether the expression of Hdac7 might be similarly altered by the
administration of SAHA in vivo, we established a quantitative real
time PCR assay (RT-qPCR) for murine Hdac7. We had previously
conducted an efficacy trial to assess the effects of the administra-
tion of SAHA, when complexed with hydroxypropyl-b-cyclodex-
trin at a concentration of 0.67 g/L in the drinking water, and
observed a considerable improvement in RotaRod performance
[23]. The WT and R6/2 mice that had been treated with SAHA
or vehicle in this experiment had been sacrificed at 13 weeks of age
and we still had access to cerebellar cDNA that had been prepared
from the brains of these mice. We were able to show that SAHA
significantly decreased the expression of Hdac7 in the cerebellum
of both wild type (WT) and R6/2 mice (Figure 1A). Therefore,
SAHA has a similar effect on the expression of Hdac7 in vivo as has
been described in cell culture and this could contribute to the
beneficial effects of SAHA administration.
Hdac7 expression level is unaffected by the expression of
the R6/2 transgene
We found heterozygous Hdac7 knockout mice to be viable and
fertile, with no overt phenotype. Therefore, prior to interpreting
the results of a genetic cross to determine whether heterozygous
knock-down of Hdac7 has a beneficial effect on R6/2 HD-related
phenotypes, it was important to show that (1) Hdac7 expression is
reduced in Hdac7+/2 knock-out mice: that Hdac7 is not auto-
regulated to wild type levels as is the case for Hdac1 [38] and (2)
that the presence of the R6/2 transgene does not alter Hdac7
expression levels. RT-qPCR was performed on cDNA prepared
from the striatum and cerebellum of 15 week old wild type (WT),
Hdac7 heterozygote (Hdac7+/2), R6/2 transgenic (R6/2) and R6/
2 mice heterozygote for Hdac7 (R6/2-Hdac7+/2) mice. We found
that Hdac7 expression levels were significantly decreased in the
striatum and cerebellum of Hdac7+/2 heterozygote mice,
irrespective of the presence of the R6/2 transgene (Figure 1B
and C). Furthermore, we saw no difference in Hdac7 expression
levels between WT and R6/2 mice in either brain region. Western
blotting was performed on whole cell lysates from 15 week
cortices. We found HDAC7 protein levels to be in agreement with
the RNA expression profiling (Figure 1D and E).
Hdac7 is expressed in neuronal populations in the mouse
brain
An important feature of the class IIa HDACs is their ability to
shuttle between the nucleus and the cytoplasm. Precise regulation
of the subcellular distribution of class IIa HDACs is intimately
linked to the control of their activity and plays a pivotal role in
cellular processes and organ development [39]. Previous observa-
tions have highlighted a differential subcellular localization of
HDAC7 in different cell lines and body tissues, suggesting that the
control of subcellular localization and function of HDAC7 differs
with respect to the cell type. To explore the expression pattern of
Hdac7 in the mouse brain we performed immunohistochemistry
to coronal sections of WT and R6/2 brains from animals at 14
weeks of age. HDAC7 is present in both the nucleus and
cytoplasm in the striatum (Figure 2), cortex and cerebellum (data
not shown) of both WT and R6/2 brains. It is present in all
neurons, but interestingly appears to be absent from the nuclei of
at least some non-neuronal cell populations.
Genetic reduction of Hdac7 does not modify the R6/2
phenotype
We have previously established a set of quantitative tests with
which to monitor progressive behavioral phenotypes in R6/2 mice
[40–42]. To generate mice for this analysis, male R6/2 mice were
bred with female Hdac7 heterozygote knock-out mice (Hdac7+/2)
to produce at least 10 female mice from each genotype (WT,
n=10; Hdac7+/2, n=13; R6/2, n=14; R6/2-Hdac7+/2,
n=12), which were born over a period of 5 days. The CAG
repeat size was well matched between the R6/2 and R6/2-
Hdac7+/2 groups (P=0.102) (Table 1). Weight gain, RotaRod
performance, grip strength and exploratory activity were moni-
tored from 4 to 15 weeks of age, and in each case, a specific test
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weeks in which measurements were taken.
Mice were weighed weekly from 4 to 15 weeks of age
(Figure 3A). As expected, R6/2 mice weighed less overall than
WT mice [F(1,45)=5.18, P=0.028] and gained weight at a slower
rate [F(4,495)=18.546, P,0.001] (Figure 3A). There was no
difference in the overall weight [F(1,45)=0.024, P=0.877] or in
weight gain [F(4,495)=1.19, P=0.316] between WT and Hdac7+/
2 mice. Genetic reduction of Hdac7 had no effect on R6/2 weight
[F(1,45)=1.064, P=0.308] and did not attenuate the rate of R6/2
weight loss [F(4,495)=1.168, P=0.327]. Therefore, genetic reduc-
tion of Hdac7 does not improve the weight loss phenotype in the
R6/2 mice.
The body temperature of the mice was recorded at 14 and 15
weeks of age by rectal probe (Figure 3B). R6/2 mice were found to
be hypothermic [F(1,45)=69.781, P,0.001], which worsened over
the course of the week between measurements [F(1,45)=4.315,
P=0.044]. There was no overall change in body temperature in
the Hdac7+/2 mice [F(1,45)=0.416, P=0.552], nor with time
[F(1,45)=2.05, P=0.159]. There was no effect of the Hdac7+/2
genotype on R6/2 body temperature [F(1,45)=1.276, P=0.265],
nor the progression of the R6/2 hypothermia [F(1.45)=0.002,
P=0.968]. Therefore, genetic reduction of Hdac7 does not
improve the hypothermia that occurs in symptomatic R6/2 mice.
RotaRod performance is a sensitive indicator of balance and
motor coordination, which has been reliably shown to decline in
R6/2 mice [40]. Using this test, we found that R6/2 and R6/2-
Hdac7+/2 mice performed similarly with age and that the
performance of Hdac7+/2 and WT mice was equivalent
(Figure 3C). Consistent with previous results, the overall RotaRod
performance of R6/2 was impaired as compared to WT [F(1
,45)=40.634, P,0.001] and deteriorated with age [F(2
,900)=9.119, P,0.001]. Overall, the performance of Hdac7+/2
mice did not differ from WT [F(1,45)=0.047, P=0.83] but did
change with age [F(2,900)=4.427, P=0.009] however, this is most
likely the result of the exceptionally good, but atypical,
performance of the WT mice at four weeks. There was no overall
effect of Hdac7 knock-down on the RotaRod performance of the
R6/2 mice [F(1 ,45)=0.194, P=0.661] and examination of the
data (Figure 3C) indicates that the statistically significant
interaction between the genotypes over the course of the
experiment [F(2,900)=4.516, P=0.009] is, once again, due to the
performance of the WT mice at 4 weeks of age and not a reflection
of an alteration in the R6/2 phenotype.
Figure 1. SAHA specifically down regulates Hdac7 mRNA levels. Hdac7 expression is decreased in Hdac7+/2 mice and not altered by the
presence of the R6/2 transgene. (A) Hdac7 mRNA expression levels are shown as relative expression ratios to the geometric mean of the Actb and
Grin1 housekeeping genes in 13 week old mouse cerebellum from SAHA-treated WT (grey) and R6/2 (black) mice together with vehicle treated WT
(white) and R6/2 (striped) mice (n.8 per genotype). Error bars are S.E.M. (B, C) Hdac7 expression level is shown as a relative expression ratio to the
geometric mean of three housekeeping genes in (B) striatum and (C) cerebellum of 14 week old wild-type (Wt, white), Hdac7+/2 knockdown
(Hdac7) (grey), R6/2 (black) and R6/2 mice with Hdac7+/2 knockdown (R6/2-Hdac7, striped) mice (n.8 per genotype). Error bars are S.E.M. (D)
Representative western immunoblot of 50 mg of cortical homogenate from 14 week old wild-type (WT), R6/2, Hdac7+/2 and R6/2-Hdac7+/2 mice.
Blots were probed with an antibody that recognizes Hdac7 (120 kDa) and a non-specific band (70 kDa). (E) Quantification of Hdac7 protein
expression levels in WT (white) and Hdac7+/2 (grey) mice. Quantification was performed on blots containing four samples per genotype using the
non-specific band for reference. Blots were additionally probed with an antibody to a-tubulin to confirm equal protein loading (data not shown).
Error bars represent standard deviation from the mean (n=4). * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0005747.g001
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of age (Figure 3D). Consistent with previous data, R6/2 mice
performed significantly worse than WT [F(1,45)=16.588,
P,0.001] and performance deteriorated with age
[F(3,360)=13.248, P,0.001]. The grip strength of Hdac7+/2 mice
was comparable to WT mice, both overall [F(1, 45)=0.474,
P=0.495] and over the course of the experiment [F(3,360)=1.055,
P=0.369]. Genetic reduction of Hdac7 did not improve R6/2 grip
strength overall [F(1,45)=0.45, P=0.833] or with age
[F(3,360)=2.131, P=0.102].
Exploratory activity was assessed fortnightly from 5 to 13 weeks
of age as described previously [41] and analyzed by repeated
measures general linear model (GLM) ANOVA. Mice were
assessed for a period of 60 min for total activity, mobility and
rearing and the P-values obtained through the analyses are
displayed in Table 2 for each parameter. Mice of all genotypes
exhibit most activity during the first 15 minutes of the assessment
period [41]. R6/2 mice show an overall hypoactivity relative to
WT mice from 11 weeks (Table 2, R6/2) although the pattern of
activity over the course of the 60 min period was significantly
different between R6/2 and WT mice (R6/2*time) by five weeks
of age. Hdac7+/2 mice were indistinguishable from WT mice,
both in overall activity (HDAC7) and in the 60 minute pattern of
activity (HDAC7*time). There was no overall improvement in
R6/2 hypoactivity through genetic reduction of Hdac7 (R6/
2*HDAC7), nor was the R6/2 pattern of hypoactivity changed
(R6/2*HDAC7*time). In summary, Hdac7 genetic reduction does
not improve hypoactivity in the R6/2 mice.
Hdac7 genetic reduction does not ameliorate the
dysregulated expression of genes of interest in R6/2
mouse brains
As HDAC inhibitors have been shown to ameliorate the
dysregulation of gene expression in HD models systems
[28,29,43], we used RT-qPCR to measure the level of expression
of a set of genes of interest in the striatum and cerebellum of WT,
R6/2, Hdac7+/2 and R6/2-Hdac7+/2 mice aged 15 weeks.
These included striatal genes that are consistently down-regulated
in mouse models of HD and in HD patient brains and cerebellar
genes that have consistently altered expression patterns in both
R6/2 and the HdhQ150 knock-in mouse model of HD [13,42,44].
We found that Hdac7 reduction did not ameliorate the transgene-
mediated transcriptional dysregulation in the striatum (Figure 4A)
or the cerebellum (Figure 4B) of 14 week old mice. However, the
expression of Igfbp5 was increased with HDAC7 reduction in the
cerebellum of WT (P=0.047) but not R6/2 mice (P=0.690)
(Figure 4B). Concomitantly, we found no difference in R6/2
transgene expression in the striatum (P=0.620) (Figure 4C) and
the cerebellum (P=0.240) (Figure 4D) of R6/2 and R6/2-
Hdac7+/2 mice.
Figure 2. HDAC7 is present in the nucleus and cytoplasm of neuronal cells in the mouse striatum. Representative confocal microscopy
images of coronal sections of brains from wild-type (WT) and R6/2 transgenic mice at 14 weeks of age immuoprobed with antibodies to NeuN to
identify neurons and with anti-HDAC7. Nuclei were visualized using TO-PRO-3 (blue). Scale bar 20 mm.
doi:10.1371/journal.pone.0005747.g002
Table 1. Details of mice used in the study.
Group Sex No. of mice CAG Repeat Size
Wild type Female 10
Hdac7+/2 Female 13
R6/2 Female 14 202 (SD 3.64)
Hdac7+/2, R6/2 Female 12 203 (SD 5.22)
doi:10.1371/journal.pone.0005747.t001
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We have previously shown that chronic administration of the
HDAC inhibitor SAHA to R6/2 mice significantly improves some
motor and neuropathological phenotypes [23]. However, the
therapeutic index of SAHA in mice is very narrow, and
therapeutic doses show considerable toxicity resulting in weight
loss in both WT and R6/2 mice. SAHA has been reported to
inhibit the eleven Zn
2+ dependent HDAC enzymes [37] and
therefore dissection of the mechanism through which SAHA exerts
its beneficial effects is complex. In order to identify the HDAC
enzyme(s) that are therapeutic targets for HD and in an attempt to
separate the beneficial effects of SAHA from its toxicity, we have
embarked on a series of genetic crosses to mice that have been
genetically engineered to knock-out specific HDAC enzymes.
HDAC7 is of additional interest because SAHA has been shown to
decrease the level of expression of HDAC7 in a number of cell lines
[34]. In this report we showed that these results extend to an in vivo
system and that, after chronic administration, SAHA down-
regulates Hdac7 mRNA levels in the brains of WT and R6/2 mice.
As nullizygosity for Hdac7 is embryonic lethal [35], it is not
possible to investigate the effects of knocking-out the Hdac7 gene
on the R6/2 phenotype. However, reduced levels of Hdac7 might
be more akin to the effects to the pharmacological inhibition of this
Figure 3. HDAC7 genetic reduction does not alter R6/2 physiological or behavioural phenotypes. The R6/2 phenotypes (A) weight loss,
(B) hypothermia, (C) impaired RotaRod performance and (D) reduced grip strength are not ameliorated by genetic knock-down of Hdac7 expression.
Error bars represent S.E.M. Shown to the right of each graph are the P values arising from GLM repeated measures ANOVA analysis of the data.
doi:10.1371/journal.pone.0005747.g003
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effects of knocking-down Hdac7 levels using Hdac7+/2 knock-out
mice would be feasible. This was necessary as it has been shown
that the effects of the genetic knock-down of Hdac1 cannot be
studied because Hdac1 mRNA and protein levels autoregulate to
that of WT mice in Hdac1+/2 mice [38] and furthermore,
nullizygosity for Hdac1 is embryonic lethal [45]. We thus
confirmed that Hdac7 expression is reduced in both the striatum
and cerebellum of Hdac7+/2 mice and that the presence of the
R6/2 transgene does not alter Hdac7 expression levels in either
Hdac7+/+ or Hdac7+/2 mice at the mRNA or protein levels. We
went on to show that genetic reduction of Hdac7 levels did not
impact on the body weight, body temperature, RotaRod
performance, grip strength or exploratory activity of R6/2 mice.
Similarly, decreased Hdac7 expression did not ameliorate the HD-
related dysregulated expression levels of a number of specific genes
of interest.
Very little is currently known about the function of HDAC7 in
brain. Hdac7 has previously been shown to be expressed
throughout the rat brain by in situ hybridization [46]. Crucially,
we established that Hdac7 is present in neurons, but were
surprised to find that it could not be detected by immunohisto-
chemistry in at least a proportion of non-neuronal brain cells.
HDAC7 together with HDACs 4, -5 and –9 comprise the class IIa
HDACs, which share a high degree of homology at their C-
terminal catalytic domain [47]. The class IIa HDACs shuttle
between the nucleus and cytoplasm and precise regulation of their
subcellular distribution plays a pivotal role in modulating their
function, via post-translational modifications such as phosphory-
lation, and the formation of nucleocytoplasmic shuttling complex-
es [31,47–60]. Of the class IIa HDACs, HDAC7 is the most
divergent [47,61]. HDAC7 has been shown to associate with
transcription co-repressors and factors such as CtBP, MEF2,
HP1a, SMRT, N-CoR, mSin3A, and HIF1a [16,31,39,47,49,57].
These interactions are consistent with the role of HDAC7 in
regulating gene expression either as a co-activator or a co-
repressor. In vitro studies with recombinant HDAC7 protein have
suggested that histones may be substrates of HDAC7 deacetylase
activity [62]. However, it has been shown that modulating
HDAC7 levels in vitro by siRNA knockdown or overexpression is
associated with growth arrest without detectable changes in
histone acetylation or p21 gene expression [34]. This would be
consistent with HDACs having many protein substrates, in
addition to histones, involved in the regulation of gene expression,
cell proliferation, and cell death and thus HDACs can be
considered to be ‘‘lysine deactelylases’’. Although the functions
of HDAC7 in brain are unknown and remain to be elucidated, our
genetic studies lead us to conclude that inhibition of Hdac7 is not a
major mediator of the beneficial effects that we obtained upon
administration of SAHA to R6/2 mice and HDAC7 should not be
prioritized as a therapeutic target for HD.
Materials and Methods
Mouse maintenance and breeding
Hemizygous R6/2 mice were bred and reared in our colony by
backcrossing R6/2 males to (CBA x C57BL/6) F1 females
(B6CBAF1/OlaHsd, Harlan Olac). Mice nullizygous for the Hdac7
gene are embryonic lethal but heterozygotes are viable and fertile.
On arrival at our facility, the Hdac7+/2 mice were on a SvEv129/
C57Bl6 mixed background and once at King’s College London
were backcrossed to (C57Bl/66CBA) F1 females seven times
before breeding with R6/2 males. All animals had unlimited
access to water and breeding chow (Special Diet Services, Witham,
UK), and housing conditions and environmental enrichment were
as previously described [40]. In the case of mice arising from the
R6/26Hdac7+/2 cross, all cages contained at least one mouse
from each genotype and mice were additionally given mash
Table 2. Statistical analysis of exploratory activity.
Factor Week Activity Mobility Rearing
Time 5 ,0.001 ,0.001 ,0.001
7 ,0.001 ,0.001 ,0.001
9 ,0.001 ,0.001 0.269
11 ,0.001 ,0.001 0.667
13 ,0.001 ,0.001 ,0.001
R6/2 5 0.374 0.260 0.068
7 0.990 0.632 0.772
9 0.315 0.045 0.536
11 0.012 0.001 0.035
13 ,0.001 ,0.001 ,0.001
Time*R6/2 5 0.224 0.357 0.448
7 0.425 0.674 0.799
9 0.096 0.033 0.104
11 ,0.001 ,0.001 0.167
13 ,0.001 ,0.001 0.052
HDAC7 5 0.579 0.973 0.307
7 0.212 0.085 0.557
9 0.128 0.116 0.740
11 0.857 0.574 0.621
13 0.506 0.497 0.915
Time*HDAC7 5 0.715 0.688 0.292
7 0.027 0.099 0.465
9 0.603 0.084 0.363
11 0.558 0.255 0.072
13 0.557 0.563 0.406
R6/2*HDAC7 5 0.689 0.397 0.774
7 0.945 0.717 0.383
9 0.643 0.688 0.779
11 0.795 0.328 0.549
13 0.312 0.113 0.753
Time*R6/2*HDAC7 5 0.106 0.371 0.470
7 0.668 0.586 0.621
9 0.418 0.509 0.428
11 0.198 0.174 0.477
13 0.143 0.174 0.214
The numbers displayed in table 2 indicate the P-values for each of the
parameters analysed (genotype of mice, age of mice and time in the activity
cages), with significant P-values highlighted for ease of interpretation. Mice in
activity cages are shown to behave differently with respect to measures of
exploratory behaviour (as determined by measuring activity, mobility and
rearing) over a period of one hour (Time). Wild-type and R6/2 mice exhibit
reproducible differences in measures of exploratory behaviour with R6/2 mice
developing a progressive hypoactivity that becomes significant at older ages as
demonstrated by decreased activity and mobility in addition to decreased
rearing behaviour (R6/2 genotype and R6/2 genotype*time). Hdac7 reduction
does not influence the behaviour of mice for any parameter assessed (Hdac 7
genotype and Hdac7*time) and furthermore, there appears no interaction
between Hdac7 and R6/2 genotypes (R6/2*Hdac7 and R6/2*Hdac7*time).
doi:10.1371/journal.pone.0005747.t002
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age. Mice were subject to a 12 h light:12 h dark cycle. All
experimental procedures were performed in accordance with
Home Office regulations.
Genotyping and CAG repeat sizing
R6/2 mice were identified by PCR of tail-tip DNA. For R6/2, a
10 ml reaction contained 100 ng DNA, 16Thermo-Start master
mix (Thermo Scientific), 1 ml DMSO, 10 ng/ml forward primer
33727 [59-CGCAGGCTAGGGCTGTCAATCATGCT-39], and
10 ng/ml reverse primer 32252 [59-TCATCAGCTTTTC-
CAGGGTCGCCAT-39]. Cycling conditions were: 15 min @
94uC, 356(30 s @ 94uC; 30 s @ 60uC, 60 s @72uC) 10 min @
72uC. The amplified R6/2 transgene product was 272 bp.
Amplification of the CAG repeat from R6/2 mouse DNA was
performed with a FAM labelled forward primer (GAGTCCCT-
CAAGTCCTTCCAGCA) and reverse primer (GCCCAAACT-
CACGGTCGGT) in 10 ml reactions containing: 0.2 mM dNTPs;
10% DMSO; AM buffer (67 mM TrisHCL pH 8.8; 16.6 mM
(NH4)S04; 2 mM MgCl2; 0.17 mg/ml BSA) and 0.5 U AmpliTaq
DNA polymerase (Applied Biosystems). Cycling conditions were:
90 s @ 94uC, 246 (30 s @ 94uC; 30 s @ 65uC; 90 s @ 72uC)
10 min @ 72uC. All instruments and materials were obtained
from Applied Biosystems unless indicated. The FAM-tagged PCR
product (1 ml) together with MegaBACE
TM ET900 (Amersham
Bioscience) internal size standard (0.04 ml) were denatured at
94uC, 5 min in 9 ml of HiDi-formamide and analysed using an
ABI3730 sequencer. Data analysis was performed using plate
manager application GeneMapper v5.2- 3730XL.
Hdac7+/2 mice were genotyped by multiplex PCR as follows: a
25 ml reaction contained 2 ml tail-tip genomic DNA (100 ng/ml),
2.5 ml2 m Md N T P s ,5 ml5 6 Promega Buffer, 1.5 ml2 5 m M
MgCl2,2 . 5mlD M S O ,1ml( o f1 0mM stock) primer ‘‘geno-SA 3’’
sequence (59–39): GTTGCAGGGTCAGCAGCGCAGGCTCTG,
0.45 ml (of 10 mM stock) primer ‘‘geno-SA 5-2’’ Sequence (59–39):
CCAGTGGACGAGCATTCTGGAGAAAGGC, 0.55 ml( o f
10 mM stock) primer ‘‘lacZ 3-2’’ Sequence (59–39): GCCAGTTT-
GAGGGGACGACGACAGTATCG, 0.2 mlP r o m e g aTaq (5 U/
ml ) ,a n d1 2 .5ml ddH2O .C y c l i n gc o n d i t i o n sw e r ea sf o l l o w s :9 5 uC,
5m i n ,3 5 6(95uC, 30 s; 60uC, 30 s; 72uC, 45 s) and 72uC, 5 min
b e f o r eh o l d i n ga t4 uC. Wild-type product size was 400 bp whereas
Het mice were indicated by a band at 640 bp.
Figure 4. Comparable changes in striatal and cerebellar gene expression changes between R6/2 and R6/2-HDAC7 mice. Relative
expression ratios to the geometric mean of three housekeeping genes [44] for transcripts in striatum (A) and cerebellum (B) of 15 week old WT
(white), Hdac7+/2 (grey), R6/2 (black) and R6/2-Hdac7 (striped) mice. Error bars correspond to S.E.M. (n.8). * P,0.05. Hdac7 genotype does not
modulate R6/2 transgene expression level in striatum (C) or cerebellum (D) of 15 week old mice R6/2 (black) and R6/2-Hdac7+/2 (striped). Error bars
correspond to S.E.M. (n.8). Cnr1, cannabinoid receptor 1; Darpp32, Dopamine and cAMP regulated neuronal phosphoprotein; Drd2, dopamine D2
receptor; Penk1, proenkephalin; Psme1, proteasome activator subunit 1 (PA28 alpha) Reg alpha; Uchl1, ubiquitin C-terminal hydrolase L1; Igfbp5,
insulin-like growth factor binding protein 5.
doi:10.1371/journal.pone.0005747.g004
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Mice were weighed weekly to the nearest 0.1 g. Motor
coordination was assessed using an Ugo Basile 7650 accelerating
RotaRod (Linton Instrumentation, UK), modified as previously
described [40]. At 4 weeks of age, mice were tested on four
consecutive days,with three trialsperday. At8,10,12and14weeks
of age, mice were tested on three consecutive days with three trials
perday.Forelimbgripstrengthwasmeasuredonce a weekat4,7,9,
11 and 13 weeks using a San Diego Instruments Grip Strength
Meter (San Diego, CA, USA) as described [40]. Exploratory,
spontaneous motor activity was recorded and assessed every two
weeks at 5, 7, 9, 11 and 13 weeks of age for 60 min during the day
using AM1053 activity cages, as described previously [41]. Briefly,
activity (total number of beam breaks in the lower level), mobility (at
least two consecutive beam breaks in the lower level) and rearing
(number of rearing beam breaks) were measured. The data were
collected and analyzed as described previously.
RNA extraction and real-time PCR expression analysis
RNA extraction and reverse transcription of 4 mg of total
cerebellar RNA and 1 mg total striatal RNA was performed as
previously described [44]. The RT reaction was diluted 10-fold in
nuclease free water (Sigma) and 5 ml was used in a 25 ml reaction
containing Precision MasterMix (PrimerDesign), 400 nM primers
and 300 nM probe using the Opticon 2 real-time PCR machine
(MJ Research). Estimation of mRNA copy number was deter-
mined in duplicate for each RNA sample by comparison to the
geometric mean of two or three endogenous housekeeping genes
as described [44]. Primer and probe sequences are available in
Supplementary Table S1.
Antibodies and western blotting
Mouse brains were rapidly frozen in liquid nitrogen and stored
at 280uC. Cortices were homogenized in ice cold buffer
containing 0.32 mM sucrose, 10 mM Tris-HCl, 50 mM KCl,
1 mM EDTA, 0.1% Triton X-100, protein inhibitor cocktail
(Roche) with the final pH adjusted to 7.8, followed by sonication
for 6610 s on ice (amplitude 30) (Vibracell Sonicator) and
centrifugation at 25006g for 15 min at 4uC. Protein concentration
was determined using the BCA assay kit (Perbio). 50 mg protein
lysates was fractionated on 8% SDS-PAGE gels and transferred
into the Protran nitrocellulose membrane (Schleicher and Schuell)
by submerged transfer apparatus (Bio-Rad) in (25 mM Tris,
192 mM glycine, 20%, v/v, methanol). Membranes were blocked
for 30 min. at RT in 5% non-fat dried milk in PBS-Tween-20,
incubated with gentle agitation over night at 4uC with the Rabbit
anti-human HDAC7 antibody raised against peptide 1-13aa
(1:250, CHDI Foundation) or alpha-Tubulin (1:40000, Sigma)
(in PBS-Tween-20 with 1% non-fat dried milk). For chemilumi-
nescent detection, blots were washed three times in PBST (PBS,
0.1% Tween-20), probed with HRP-linked secondary antibodies
(HRP conjugated anti-rabbit mouse or anti-antibody (1:3000,
Dako) (in PBS-Tween20 with 1% non-fat dried milk) for 1 h at RT
and washed three times in PBST. Protein was detected by
chemiluminescense (Femto WB detection system (Pierce) accord-
ing to the manufacturer’s instructions. The signals were quantified
using a GS-800 calibrated densitometer (Bio-Rad).
Immunohistochemistry and confocal microscopy
Whole brains were frozen in isopentane, stored at 80uCa n d
15 mm thick sections were cut using a cryostat (Bright Instruments
Ltd.). Sections were fixed for 10 min in methanol at 220uCa n d
washed twice in 0.1 M phosphate buffered saline pH 7.4 (PBS) for
15 min before blocking in PBS containing 2% bovine serum
albumin (BSA) and 0.1% Triton-X for 15 min. Sections were
incubationinprimaryantibodiesinPBSwithBSAovernightat4uC,
washed twice in PBS for 15 min, incubated in secondary fluorescent
antibodies in PBS with BSA for 1 hr at room temperature and
washed twice in PBS for 15 min. Primary antibodies were: HDAC7
(rabbit polyclonal Sigma H2662) (1:50) and NeuN (mouse
monoclonal Chemicon MAB377) (1:200) and secondary antibodies
were:Alex-555donkeyanti-rabbit(1:1000)and Alexa488goat anti-
mouse (1:1000) respectively (Molecular Probes). Nuclei were
visualized using TO-PRO-3 (Molecular Probes) (1:1000). Slides
weremountedinMowialandantibodylocationwasvisualizedusing
an LSM150 Meta confocal microscope (Zeiss).
Statistical analysis
Statistic analysis was performed by Student’s t-test (Excel or
SPSS), one-way ANOVA, two-way ANOVA and repeated
measures GLM ANOVA, with the Greenhouse–Geisser correc-
tion for non-sphericity using SPSS.
Supporting Information
Table S1 Sequences of primers and Taqman probes used in real-
time PCR assays. KEY: Cnr1 (Cannabinoid receptor 1); Darpp32
(Dopamine and cAMP regulated neuronal phosphoprotein, also
known as Ppp1r1b, protein phosphatase 1, regulatory subunit 1B);
Drd2 (Dopamine D2 receptor); Hdac (histone deacetylase); Htt
(Human Huntington’s disease gene, used to detect human exon 1
transgene); Igfbp5 (insulin-like growth factor binding protein 5
precursor);Pcp4(Purkinje cellprotein 4);Penk1(Preproenkephalin);
Uchl1 (ubiquitin carboxyl-terminal hydrolase L1).
Found at: doi:10.1371/journal.pone.0005747.s001 (0.03 MB
DOC)
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